AstraZeneca’s Tezepelumab Study Targets Real-World Gains in Chronic Sinus Disease

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.

The study “Open-label Single-arm, Non-interventional, Multi-centre Study for Evaluation of Clinical and Patient Reported Outcomes in Adult Patients With CRSwNP on Tezepelumab” tracks how tezepelumab works in routine care for chronic rhinosinusitis with nasal polyps in Russia. It aims to measure symptom relief and patient quality of life, giving investors a clearer view of real-world performance beyond controlled trials.

The treatment under review is tezepelumab, a biologic drug developed by AstraZeneca to manage severe inflammatory airway disease. In this setting it is used for chronic rhinosinusitis with nasal polyps, with or without asthma, to reduce symptoms and improve day‑to‑day function.

This is an observational, open-label, single-arm cohort study, so doctors and patients know they are using tezepelumab and there is no comparison group. The design simply follows patients who have started the drug in normal clinical practice and records clinical outcomes and patient feedback over time.

The study uses a retrospective-prospective approach, meaning it looks back at recent medical records and then follows patients forward after they begin tezepelumab. This real-world angle is important for investors because it shows how the drug may perform across broader, less selected patient groups than in Phase 3 trials.

The trial start (first submitted 24 November 2025) marks AstraZeneca’s move to deepen evidence in upper airway disease beyond asthma. The latest update on 2 March 2026 confirms the status as recruiting, signaling that data collection is underway but headline results are not yet available.

Primary completion and overall completion dates are not yet reported, so investors should treat this as an early to mid-stage evidence build rather than a near-term catalyst. Timelines suggest that meaningful readouts will likely emerge after recruitment and follow-up close, which could still be several quarters away.

For AstraZeneca, strong real-world data in chronic rhinosinusitis with nasal polyps could support broader use of tezepelumab and strengthen its respiratory and immunology portfolio. Positive outcomes may help extend the drug’s lifecycle, improve pricing discussions, and defend share against biologic rivals targeting similar inflammatory pathways.

Competitors like Sanofi and Regeneron with dupilumab, and other biologic players in respiratory disease, will be key reference points for investors assessing upside. If tezepelumab shows strong real-world benefits in this niche, it could support premium positioning in severe airway disease and modestly lift sentiment on AZN over the medium term.

The study is currently recruiting and actively updated, with further details and ongoing status available on the ClinicalTrials portal.

To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.